Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early versus delayed start of arimoclomol in sporadic inclusion body myositis (post-IBM4809)
2019-000749-11Phase 3Unknown
- Sponsor
- Orphazyme A/S
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of arimoclomol in sporadic inclusion body myositis (sIBM) (2 arms), sponsored by Orphazyme A/S. Status: unknown.
02
Drugs
arimoclomol
03
Conditions
sporadic inclusion body myositis (sIBM)
Beyond the preview
Go deeper on 2019-000749-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000749-11.